Long-term survival and post-hoc analysis of toripalimab plus definitive chemoradiotherapy for oesophageal squamous cell carcinoma: insights from the EC-CRT-001 phase II trialResearch in context

Long-term survival and post-hoc analysis of toripalimab plus definitive chemoradiotherapy for oesophageal squamous cell carcinoma: insights from the EC-CRT-001 phase II trialResearch in context

Summary: Background: In the EC-CRT-001 phase II study, the combination of toripalimab (an anti-programmed death-1 antibody) and definitive chemoradiotherapy (CRT) has shown promising efficacy in patients with locally advanced oesophageal squamous cell carcinoma (ESCC). Here, we reported the long-te...

Full description

Bibliographic Details
Main Authors: Ruixi Wang, Yihong Ling, Baoqing Chen, Yujia Zhu, Yonghong Hu, Mengzhong Liu, Yadi Yang, Li Zhang, Yingxin Lv, Shiliang Liu, Qiaoqiao Li, Mian Xi
Format: Article
Language:English
Published: Elsevier 2024-09-01
Series:EClinicalMedicine
Subjects:
Oesophageal squamous cell carcinoma
Definitive chemoradiotherapy
Toripalimab
Immune-related adverse event
Survival
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537024003857

Internet

http://www.sciencedirect.com/science/article/pii/S2589537024003857

Similar Items